Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: The APPEAL trial

International Journal of Rheumatic Diseases

Volumn 15, Issue 2, 2012, Pages 188-196

  Kim, Ho Youn ^a   Hsu, Ping Ning ^b   Barba, Merle ^c   Sulaiman, Wahinnuddin ^d   Robertson, Debbie ^e   Vlahos, Bonnie ^e   Khandker, Rezaul ^e   Nab, Henk ^f   Freundlich, Bruce ^g   Koenig, Andrew ^e  

^a The Catholic University of Korea   (South Korea)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c Cebu Doctors Hospital   (Philippines)

^d HOSPITAL RAJA PERMAISURI BAINUN   (Malaysia)

^e PFIZER INC   (United States)

^f Pfizer Asia Pacific   (Malaysia)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Asia Pacific; Efficacy; Etanercept; Rheumatoid arthritis; Safety

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART DISEASE; HUMAN; INFECTION; INFESTATION; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PHYSICIAN; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; UNITED STATES; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PACIFIC ISLANDS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859268784     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01680.x     Document Type: Article

References (28)

1. Silman AJ, Hochberg MC (2001) Epidemiology of the Rheumatic Diseases, 2nd edn, pp 31-71. Oxford University Press, Oxford.
2. Chandrasekaran AN, Radhakrishna B (1995) Rheumatoid arthritis and connective tissue disorders: India and South-East Asia. Baillière's Clin Rheumatol9, 45-57.
3. Saag KG, Teng GG, Patkar NM, et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum59, 762-84.
4. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet1, 1036-8.
5. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS (1998) Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132months of therapy. J Rheumatol25, 238-42.
6. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A (1995) Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol13, 589-93.
7. Cuchacovich M, Soto L (2002) Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis61, 942-3.
8. Clegg DO, Reda DJ, Weisman MH, et al. (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum39, 2004-12.
9. Amor B, Dougados M, Khan MA (1995) Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am21, 117-28.
10. Klareskog L, van der Heijde D, de Jager JP, et al. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet363, 675-81.
11. Emery P, Breedveld FC, Hall S, et al. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet372, 375-82.
12. Combe B, Landewe R, Lukas C, et al. (2007) EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis66, 34-45.
13. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YPM, et al. (2009) Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis68, 1153-8.
14. van der Kooij SM, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, et al. (2009) Drug-free remission, functioning and radiographic damage after 4years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis68, 914-21.
15. van den Berg WB (2001) Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum30, 7-16.
16. Moreland LW, Baumgartner SW, Schiff MH, et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med337, 141-7.
17. Mok C (2005) Consensus statement on the indications and monitoring of anti-tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong (for the working group on the use of TNF inhibitors for the treatment of rheumatic diseases in Hong Kong). Hong Kong Bull Rheum Dis5, 19-25.
18. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum31, 315-24.
19. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992) The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum35, 498-502.
20. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum41, 1845-50.
21. Fransen J, Creemers MCW, van Riel P (2004) Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology43, 1252-5.
22. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum39, 34-40.
23. Felson DT, Anderson JJ, Boers M, et al. (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum38, 727-35.
24. Strangfeld A, Listing J, Herzer P, et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA301, 737-44.
25. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. (2006) Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis - Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum54, 1063-74.
26. Koike T, Harigai M, Inokuma S, et al. (2009) Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol36, 898-906.
27. Smolen JS, Kalden JR, Scott DL, et al. (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet353, 259-66.
28. Smolen JS, Landewe R, Breedveld FC, et al. (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis69, 964-75.